The Latest Breaking News from AbbVie

Despite headwinds from Humira patent expiry, potential price controls from the Inflation Reduction Act, and recent underperformance relative to the S&P 500, Wall Street analysts anticipate moderate gains in Abbvie stock.

With a strong product portfolio, this growth and income stock is an excellent long-term investment.

June S&P 500 E-Mini futures (ESM24) are up +0.63%, and June Nasdaq 100 E-Mini futures (NQM24) are up +0.86% this morning as upbeat quarterly results from tech titans Alphabet and Microsoft boosted sentiment, while investors geared up for the release of the Fed’s preferred inflation gauge.

The pharmaceutical industry is expected to expand significantly due to the ever-rising global medical needs and technological advances. In this scenario, let’s analyze the better investment option between popular pharma stocks, Merck &Co (MRK) and AbbVie (ABBV).

The CDC warned doctors about "counterfeit or mishandled" Botox injections that have caused clusters of illness in the U.S.

AbbVie stock has slumped 9% off its record high in March and is facing increasingly steep competition for its biggest moneymaker, Humira.

Public health authorities are investigating reports of counterfeit injections sickening 19 people across nine states. Experts say getting bona fide Botox starts with finding a trustworthy provider.

Officials said that all the incidents involved women who reported sick following the administration of counterfeit Botox injections of AbbVie or those who received injections from unlicensed or untrained individuals in non-healthcare environments.

Investors can consider adding defensive stocks, such as AbbVie and Verizon, to their equity portfolios in 2024 to help shield against heightened stock market volatility.